348150 — KoBioLabs Income Statement
0.000.00%
Last trade - 00:00
- KR₩153bn
- KR₩128bn
- KR₩33bn
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 577 | 4,591 | 2,893 | 11,606 | 33,138 |
Cost of Revenue | |||||
Gross Profit | 288 | 2,642 | 1,909 | 8,021 | 23,731 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 7,928 | 16,928 | 19,238 | 31,892 | 51,576 |
Operating Profit | -7,352 | -12,336 | -16,344 | -20,286 | -18,438 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -44,067 | -55,072 | -16,368 | -23,030 | -14,683 |
Provision for Income Taxes | |||||
Net Income After Taxes | -44,067 | -55,072 | -15,382 | -23,386 | -15,158 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -44,067 | -55,072 | -15,382 | -21,921 | -13,853 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -44,067 | -55,072 | -15,382 | -21,921 | -13,853 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -2,859 | -3,549 | -945 | -1,305 | -748 |
Dividends per Share |